

Consolidated Financial Statements and Supplementary Financial Information

June 30, 2024 and 2023

(With Independent Auditors' Report Thereon)

Table of Contents

	Page(s)
Independent Auditors' Report	1–2
Consolidated Financial Statements:	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	4–5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7–28
Supplementary Financial Information	
Schedule 1 – Consolidating Balance Sheet	29–30
Schedule 2 – Consolidating Statement of Operations and Changes in Net Assets	31–32



KPMG LLP 750 East Pratt Street, 18th Floor Baltimore, MD 21202

Independent Auditors' Report

The Board of Directors Meritus Health, Inc.:

Opinion

We have audited the consolidated financial statements of Meritus Health, Inc. and its subsidiaries (the Company), which comprise the consolidated balance sheets as of June 30, 2024 and 2023, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2024 and 2023, and the results of its operations and changes in net assets and its cash flows for the years then ended in accordance with U.S. generally accepted accounting principles.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with U.S. generally accepted accounting principles, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the consolidated financial statements are issued.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.



In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether
 due to fraud or error, and design and perform audit procedures responsive to those risks. Such
 procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the
 consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that
 are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
 effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that
 raise substantial doubt about the Company's ability to continue as a going concern for a reasonable
 period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The supplementary information in Schedules 1 and 2 is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with GAAS. In our opinion, the information is fairly stated in all material respects in relation to the consolidated financial statements as a whole.

KPMG LLP

Baltimore, Maryland October 31, 2024

Consolidated Balance Sheets

June 30, 2024 and 2023

(Dollars in thousands)

Assets		2024	2023
Current assets: Cash and cash equivalents Short-term investments Current portion of assets whose use is limited Accounts receivable Supplies Prepaid and other current assets	\$	12,640 89,009 62,614 61,932 12,025 25,524	43,495 127,770 11,049 45,096 7,899 15,360
Total current assets		263,744	250,669
Assets whose use is limited Property, plant, and equipment, net Equity investments in affiliates Other assets		288,560 299,506 43,983 46,524	254,960 236,698 63,492 42,933
Total assets	\$	942,317	848,752
Liabilities and Net Assets			
Current liabilities: Accounts payable and accrued expenses Accrued salaries, wages, and withholdings Accrued compensation benefit Advances from third-party payors Accrued interest payable Current portion of long-term debt	\$	52,391 14,389 14,420 17,056 5,314 8,759	28,296 11,648 15,026 17,303 5,442 8,491
Total current liabilities		112,329	86,206
Long-term debt, net of current portion Accrued retirement benefits Other long-term liabilities	_	277,146 8,891 41,716	285,905 6,451 33,613
Total liabilities		440,082	412,175
Net assets: Net assets without donor restrictions Net assets with donor restrictions		490,751 11,484	425,952 10,625
Total net assets		502,235	436,577
Total liabilities and net assets	\$	942,317	848,752

See accompanying notes to consolidated financial statements.

Consolidated Statements of Operations and Changes in Net Assets

Years ended June 30, 2024 and 2023

(Dollars in thousands)

	 2024	2023
Unrestricted revenue, gains, and other support:		
Net patient service revenue	\$ 579,606	502,005
Other revenue	27,609	37,474
Equity earnings in affiliates	14,189	15,862
Net assets released from restriction used for operations	 182	154
Total unrestricted revenue, gains, and other support	 621,586	555,495
Operating expenses:		
Salaries and wages	282,520	241,527
Employee benefits	51,744	46,101
Professional fees	45,456	41,510
Supplies and other	176,228	150,201
Interest	11,688	11,864
Depreciation and amortization	 30,646	29,733
Total expenses	 598,282	520,936
Operating income	23,304	34,559
Nonoperating gains (losses), net:		
Investment returns, net	41,172	26,936
Other, net	 (1,529)	(2,022)
Excess of revenues over expenses	\$ 62,947	59,473

Consolidated Statements of Operations and Changes in Net Assets

Years ended June 30, 2024 and 2023

(Dollars in thousands)

	 2024	2023
Net assets without donor restrictions:		
Excess of revenues over expenses	\$ 62,947	59,473
Other, net	 1,852	516
Increase in net assets without donor restrictions	 64,799	59,989
Net assets with donor restrictions		
Contributions	2,100	10,245
Other, net	(109)	(3,854)
Net assets released from restriction for capital	(950)	
Net assets released from restriction for operations	 (182)	(154)
Increase in net assets with donor restrictions	 859	6,237
Increase in net assets	65,658	66,226
Net assets:		
Beginning of year	 436,577	370,351
End of year	\$ 502,235	436,577

See accompanying notes to consolidated financial statements.

Consolidated Statements of Cash Flows

Years ended June 30, 2024 and 2023

(Dollars in thousands)

		2024	2023
Cash flows from operating activities:			
Increase in net assets	\$	65,658	66,226
Adjustments to reconcile increase in net assets to net cash provided by operating activities:			
Depreciation and amortization		30,646	29,733
Net realized and unrealized gains on investments		(31,994)	(21,179)
Gain on disposal of assets		(19)	(3)
Equity earnings in affiliates		(14,189)	(15,862)
Restricted contributions and other		(3,866)	(6,907)
Changes in assets and liabilities:			
Accounts receivable		(16,836)	(3,023)
Supplies, prepaid, and other current assets		(14,283)	982
Other assets		(3,391)	(631)
Accounts payable, accrued expenses, and other long-term liabilities		21,202	(1,290)
Accrued salaries, wages, and withholdings		2,741	(3,168)
Accrued compensation benefit		(606)	761
Advances from third-party payors		(247)	(12,032)
Interest payable		(128)	(145)
Accrued retirement benefits		2,440	829
Net cash provided by operating activities		37,128	34,291
Cash flows from investing activities:			
Purchase of property, plant, and equipment		(82,439)	(26,630)
Proceeds from the disposal of assets		_	3
Sales of other short-term investments, and assets whose use is limited, net		(38,058)	17,847
Purchases of alternative investments		(36,551)	(40,404)
Sales of alternative investments		71,674	37,376
Equity contributions to affiliates, net		33,698	3,255
Net cash used in investing activities	_	(51,676)	(8,553)
Cash flows from financing activities:			
Payments on long-term debt and finance leases		(8,491)	(5,841)
Restricted contributions and other		3,659	2,739
Net cash used in financing activities		(4,832)	(3,102)
Net (decrease) increase in cash and cash equivalents		(19,380)	22,636
Cash, cash equivalents, and restricted cash:			
Beginning of year	_	43,495	20,859
End of year	\$ 	24,115	43,495
Cash and cash equivalents	\$	12,640	43,495
Cash included in short term investments and assets limited to use		11,475	
Cash, cash equivalents, and restricted cash at end of year	\$	24,115	43,495
Supplemental disclosure of cash flow information:			
Cash paid for interest	\$	11,688	11,864
Cash paid for income taxes	•	108	277
Amount included in accounts payable for construction in progress		10,996	84
Non-cash restricted contributions and other		207	4,168

See accompanying notes to consolidated financial statements.

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

(1) Description of Organization

Organization

Meritus Health, Inc. (MHI or the Company) is the parent corporation of the Meritus Medical Center, Inc. (the Hospital), Meritus Health Foundation, Inc. (the Foundation) and MSOM, Inc. (MSOM). The Hospital is the parent corporation of the Meritus Insurance Company, Ltd. (MIC); Meritus Health ACO, LLC (MACO); and Meritus Holdings, LLC (Holdings), which owns Meritus Enterprises (MEI). These entities are collectively referred to as "Meritus."

The Hospital is a not-for-profit acute-care hospital located in Hagerstown, Maryland and serves the residents of western Maryland, southern Pennsylvania, and the panhandle of West Virginia. The Hospital currently offers acute general hospital inpatient services, including adult medical/surgical care, obstetrics and newborn care, including a family birthing center, cardiac catheterizations, comprehensive inpatient rehabilitation, radiology and diagnostic services, inpatient and outpatient mental health services, a regional Level III Trauma Center, an intensive care unit, an intermediate care unit, and a pediatric unit. The Hospital also manages gifts, donations, or bequests given for the benefit of Meritus and owns real estate properties for rental to medical provider entities and development opportunities.

The Foundation is a not-for-profit corporation whose purpose is to raise philanthropic support for the capital and endowment campaigns of the Hospital and MSOM. The Foundation also raises money for the Hospital's medical programs, healthcare objectives, scientific research, educational programs, and related community activities. Resources for the Foundation's activities are primarily provided by donors.

MIC is a Cayman Island captive insurance company, wholly owned by the Hospital that provides primary limits of insurance to Meritus for professional liability, employed physician's professional liability, comprehensive general liability, deductible, and stop-loss coverage for health insurance.

As of June 30, 2024, MEI, a for-profit corporation, held ownership interests in the following joint venture:

Diagnostic Imaging Services, LLC (DIS), an outpatient imaging services provider

Holdings is the sole member of Medical Practices of Antietam, LLC, which employs physicians and operates clinics in the Meritus primary service area.

As of June 30, 2024, Holdings, held ownership interests in the following joint venture:

General Surgery Real Estate, LLC (GSRE), a real estate holding company

MEI also owns and operates Equipped for Life (EFL), a durable medical equipment company.

MACO is an Accountable Care Organization (ACO), wholly owned by the Hospital. MACO participates in the following CMS programs:

 Maryland Primary Care Program (MDPCP), as an approved Care Transformation Organization for Washington County, MD, effective January 1, 2019

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

MSOM, Inc. (Meritus School of Osteopathic Medicine) was established to operate a school of osteopathic medicine. MSOM, Inc. received conditional approval from the Maryland Higher Education Commission to operate as an in-state degree-granting institution and pre-accreditation from the Commission on Osteopathic College Accreditation. Medical school enrollment trends indicate an ample supply of qualified applicants to support the proposed class size of 180 students. The school is under construction, and the first class is planned to begin in August 2025. The Meritus Board of Directors have approved financial commitments totaling \$190,000, including a reserve obligation of \$50,000. Meritus will fund the project through current cash and investment holdings.

The Hospital is building a student housing development adjacent to the campus. Phase 1 of the project has an expected completion date of the summer of 2025 with 180 one and two bedroom units. Phase 2 of the project will increase the residential complex to 364 units. Phase 1 and 2 will cost approximately \$90,000.

(2) Summary of Significant Accounting Policies

(a) Principles of Consolidation

The Company's consolidated financial statements include the subsidiaries in which the Company has more than 50% voting interests or when the Company is deemed to have control. Significant intercompany accounts and transactions have been eliminated in consolidation. The accompanying consolidated financial statements include the accounts of MHI, the Hospital, Holdings, MEI, the Foundation, MACO, MSOM, and MIC. All material intercompany balances and transactions have been eliminated in consolidation.

(b) Use of Estimates

The preparation of consolidated financial statements, in conformity with accounting principles generally accepted in the United States of America, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

(c) Cash and Cash Equivalents

Cash and cash equivalents consist of short-term, highly liquid investments held with large well-known financial institutions, that are readily convertible to cash and have original maturities of three months or less. Cash and cash equivalents are carried at cost that approximates fair value.

(d) Patient Accounts Receivable

Patient accounts receivable result from the healthcare services provided by Meritus and are recorded at the net realizable value based on certain assumptions determined by each payor. For third-party payors, including Medicare, Medicaid, and commercial insurance, the net realizable value is based on the estimated contract adjustments, which is based on approved discounts on charges as permitted by the Health Services Cost Review Commission (HSCRC). For self-pay accounts, which included patients who are uninsured and the patient responsibility portion for patients with insurance, the net realizable value is determined using estimates of historical collection experience. See note 2(m) for revenue recognition policies.

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

(e) Assets Whose Use is Limited

Assets whose use is limited include assets set aside by the Board of Directors for specific purposes, for supplemental retirement benefit investments, to fulfill donor purposes, assets held by trustees under bond indenture agreement, and funds designated for insurance purposes. Amounts required to meet current liabilities are shown as current assets in the consolidated balance sheets. Cash and cash equivalents, as defined above, within assets whose use is limited are treated as investments.

(f) Investments and Investment Income

Investments in equity securities (i.e., investments that have readily determinable fair values and are not accounted for by the equity method) and all investments in debt securities are reported at fair value on the consolidated balance sheets. Institutional funds are recorded at their readily determinable fair values (RDFV). All securities with the exception of alternative investments are reported at fair value. Alternative investments are recorded under the equity method of accounting.

A significant portion of Meritus' investments are held in an investment portfolio maintained for the benefit of Meritus and its affiliates and its subsidiaries. Investments are classified as trading securities except for certain investments, which are limited or restricted as to use or do not have the liquidity to qualify as trading securities and are classified as investments available for sale.

Investment income and realized gains are recorded as nonoperating revenue. Unrealized gains and losses on trading securities are recorded as nonoperating revenue. Unrealized gains and losses on available for sale investments are included in other changes in net assets. Investment income and realized gains and losses on assets restricted by donors for specific purposes or endowment are included in net assets with donor restrictions.

Investment income, which includes interest and dividends, on proceeds of borrowings that are held by a trustee are reported as other revenue. Other investment income, which includes interest, dividends and realized and unrealized gains and losses on assets limited as to use by Board of Directors, and funds designated for insurance purposes are recorded as nonoperating gains (losses), net, unless the income or loss is restricted by donor or law.

Meritus' investments are managed by investment managers. Investment securities, in general, are exposed to various risks, such as interest rate, credit, and overall market volatility. Due to the level of risk associated with certain investment securities, it is reasonably possible that changes in the values of investment securities will occur in the near term and that such change could materially affect the amounts reported in the consolidated financial statements.

(g) Supplies

Supplies for the Hospital are carried at cost on a weighted average basis.

(h) Property, Plant and Equipment

Property, plant and, equipment acquisitions are recorded at cost. Those assets acquired by gift are carried at amounts established as fair value at the time of acquisition. Depreciation is provided over the estimated useful life of each class of depreciable assets and is computed using the straight-line

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

method. Equipment under finance leases are amortized by the straight-line method over the shorter of the lease term or the estimated useful life of the equipment. Such amortization is included in depreciation and amortization in the consolidated financial statements. Interest cost incurred on borrowed funds during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. No interest was capitalized during the year ended June 30, 2024 or 2023. Leasehold improvements are amortized over the lesser of the useful life or the lease life. Durable medical equipment held for resale is included in supplies. The remainder of durable medical equipment is rented to patients and is included in property, plant, and equipment. Assets are retired or disposed of at book value and related gains or losses are recorded for assets sold. Useful lives range as follows:

Land improvements 5–25 Years
Buildings 10–40 Years
Equipment 3–20 Years

Gifts of long-lived assets such as land, buildings, or equipment are reported as other changes in net assets without donor restrictions unless explicit donor stipulations specify how the donated assets must be used. When applicable, gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as restricted support. Absent explicit donor stipulations about how long-lived assets must be maintained, expirations of donor restrictions, occur when the donated or acquired long-lived assets are placed into service.

Meritus continually evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets is appropriate, or whether the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, Meritus uses an estimate of the related undiscounted operating income over the remaining life of the long-lived asset in measuring whether the long-lived asset is recoverable.

The impairment loss on these assets is measured as the excess of the carrying amount of the asset over its fair value. Fair value is based upon market prices, where available, or discounted cash flows. Management believes that no revision to the remaining useful lives is required, and there was no impairment of long-lived assets during the years ended June 30, 2024 or 2023.

(i) Deferred Financing Costs

Financing costs incurred in issuing debt have been capitalized and are being amortized over the life of the debt.

(j) Compensated Absences

Meritus records a liability for amounts due to employees for future absences, which are attributable to services performed in the current and prior periods. This liability is included in accrued compensation benefit on the consolidated balance sheets.

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

(k) Net Assets with Donor Restrictions

Net assets with donor restrictions are those whose use by Meritus have been limited by donors to a specific time period or purpose. When donor restrictions expire, that is, when a time restriction ends or a purpose restriction is accomplished, net assets with donor restrictions are reclassified into net assets without donor restrictions and reported as net assets released from restrictions. Net assets with donor restrictions also include funds that have been restricted by donors to be maintained by Meritus in perpetuity.

Donor-restricted contributions whose restrictions are met within the same year as received are reported as unrestricted contributions if for operating purposes and as other changes in net assets without donor restrictions if for capital purposes in the consolidated statements of operations and changes in net assets.

(I) Excess of Revenues Over Expenses

The consolidated statements of operations include a performance indicator, the excess of revenue over expenses. Changes in net assets without donor restrictions that are excluded from the excess of revenues over expenses, consistent with industry practice, include net assets released from restrictions for property, plant, and equipment.

(m) Net Patient Service Revenue

For services provided at the Hospital's campus, all payors are required to pay the HSCRC approved rates. Net patient service revenue is reported at the estimated net realizable amounts from patients, third-party payors, and others for services rendered.

The Hospital's charges are subject to review and approval by the HSCRC. The total rate of reimbursement for services to patients under the Medicare and Medicaid programs is based on an arrangement between the Centers for Medicare and Medicaid Service and the HSCRC. The Hospital has an agreement with the HSCRC under a rate regulation concept called Global Budget Revenue (GBR).

Services not located on the Hospital's campus and certain other services are not regulated by the HSCRC. Medicare and Medicaid pay the revenues associated with these services based upon established fee schedules. Commercial payors pay at negotiated rates for these services.

Laws and regulations governing the HSCRC, Medicare, and Medicaid programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Meritus believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no such regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action.

Net patient service revenue is recognized, over time, as performance obligations are satisfied. Performance obligations are determined based on the nature of the services provided. Revenue for

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

performance obligations satisfied over time is recognized at the estimated net realizable amounts from patients and third-party payors for services rendered.

The Company generates revenues, primarily by providing healthcare services to its customers. Revenues are recognized when control of the promised good or service is transferred to customers, in an amount that reflects the consideration to which the Company expects to be entitled from patients, third-party payors (including government programs and insurers), and others, in exchange for those goods and services.

The majority of the Company's healthcare services represent a bundle of services that are not capable of being distinct and as such, are treated as a single performance obligation satisfied over time as services are rendered. The Company also provides certain ancillary services that are not included in the bundle of services, and as such, are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.

The Company's estimate of the transaction price includes estimates of price concessions for such items as contractual allowances, charity care, potential adjustments that may arise from payment and other reviews, and uncollectible amounts, which are determined using a portfolio approach as a practical expedient to account for patient contracts as collective groups rather than individually. Estimates for uncollectible amounts are based on the aging of the accounts receivable, historical collection experience for similar payors and patients, current market conditions, and other relevant factors.

Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to net patient service revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payor's or patient's ability to pay are recorded as bad debt expense. Bad debt expense for the years ended June 30, 2024 or 2023 was not significant to the consolidated financial statements.

Patient service revenue for the years ended June 30, 2024 and 2023, net of contractual allowances and other allowances, recognized in the period by inpatient/outpatient, is as follows:

	 Third party		
	2024	2023	
Net patient service revenue:			
Hospital inpatient	\$ 259,274	231,917	
Hospital outpatient	228,523	208,429	
Other outpatient	 395,691	318,694	
Gross charges	883,488	759,040	
Less contractual and other allowances	 (303,882)	(257,035)	
Net patient service revenue	\$ 579,606	502,005	

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

(n) Charity Care

Meritus provides care to patients who meet certain criteria under its charity care policy without charge or at amounts less than its established rates. Meritus does not pursue collection on amounts deemed to qualify as charity. Meritus also estimates that the direct and indirect cost of services and supplies furnished to patients eligible for charity care using a ratio of cost to gross charges based on internal data is \$22,057 and \$14,479 for the years ended June 30, 2024 and 2023, respectively.

Meritus' patient acceptance policy is based upon its mission statement and its charitable purposes. This policy results in Meritus' assumption of higher-than-normal credit risk from its patients. To the extent that Meritus realizes additional losses resulting from such higher credit risks and clients are not identified or do not meet Meritus' defined charity care policy, such additional losses are recognized as a reduction to net patient service revenue.

Meritus also sponsors certain other charitable programs, which provide substantial benefit to the broader community. Such programs include services to needy and elderly populations that require special support, as well as health and education for the general community welfare. In addition, all other uncollectible amounts resulting from the patients' inability to pay are recorded as a reduction to net patient service revenue, consistent with Meritus' policy.

(o) Other Revenue

Other revenue comprises rental income, gains and losses on disposal of assets, 340B contract pharmacy income, grants related to COVID-19 funding, including funding from the Coronavirus Aid, Relief, and Economic Security (CARES) Act and Federal Emergency Management Agency (FEMA) reimbursement, and other miscellaneous items.

The Company received \$5,492 in CARES Act payments on August 24, 2022 and recognized the amount in other revenue for the year ended June 30, 2023.

On August 9, 2022, the Company received a letter of final determination from FEMA in the amount of \$10,498, which was recognized in other revenue for the year ending June 30, 2023.

On July 6, 2023, the Company received a letter of final determination from FEMA in the amount of \$2,461, which was recognized in other revenue for the year ending June 30, 2024.

On January 31, 2024, the Company received a letter of final determination from FEMA in the amount of \$2,619, which was recognized in other revenue for the year ending June 30, 2024.

(p) Income Taxes

The Internal Revenue Service has ruled that the Hospital and the Foundation qualify under Section 501(c)(3) of the Internal Revenue Code and are, therefore, not subject to tax under present income tax regulations.

Holdings and MACO are considered a disregarded entity for tax purposes and are reported through the Hospital.

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

MEI accounts for income taxes through the current recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between tax bases and financial reporting bases of other assets and liabilities.

At present, no income, profit, or capital gain taxes are levied in the Cayman Islands and accordingly, no provision for taxation has been made for MIC. In the event that such taxes are levied, MIC has been granted an exemption until September 14, 2043 for any such taxes that might be introduced. MIC intends to conduct its affairs so as not to be liable for taxes in any other jurisdiction.

Meritus follows the accounting guidance for uncertainties in income tax positions, which requires that a tax position be recognized or derecognized based on a "more-likely-than-not" threshold. This applies to positions taken or expected to be taken in a tax return. Meritus does not believe its consolidated financial statements include any material uncertain tax positions. As of June 30, 2024, the Meritus tax years ended June 30, 2021, through June 30, 2024, for federal tax jurisdiction remain open to examination.

(q) Concentration of Credit Risk

Meritus invests its excess cash, investments, and assets in financial institutions, which are federally insured under the Federal Deposit Insurance Act (FDIA). Deposits in certain accounts exceed federally insured deposit limits. Meritus has experienced no losses on its deposits and believes it is not exposed to any significant credit risks on its cash deposits.

Meritus grants credit without collateral to the patients it serves who primarily live in the tristate area. The majority of these patients have either insurance through Blue Cross, another insurance company or a health maintenance organization, or qualify for the Maryland Medical Assistance or the Centers for Medicare and Medicaid Services (CMS) programs.

At June 30, Meritus' patient accounts receivable was made up of the following:

	2024	2023
Medical assistance HMO/Medicaid	12 %	14 %
Medicare	38	41
Commercial insurance, HMO, and other	30	26
Blue Cross/Blue Shield	15	14
Self-pay	5	5
	100 %	100 %

(r) Deferred Compensation Plan

The Hospital is party to a 457(b) deferred compensation plan and a 457(f) deferred compensation plan, both are intended to provide retirement benefits to certain eligible employees. Assets are deposited with the plan managers, pursuant to this agreement, such that the value of the assets determined by the fair value approximately equals the related accrued deferred compensation liability. The funds are

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

placed into a range of investment strategies from conservative to aggressive. The liability associated with this plan is included in accrued retirement benefits on the consolidated balance sheets.

(s) Management's Assessment and Plans

The Company previously adopted Accounting Standards Update (ASU) No. 2014-15, *Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern* (ASU 2014-15). ASU 2014-15 requires management to evaluate an entity's ability to continue as a going concern within one year after the date that the financial statements are issued (or available to be issued, when applicable). Management determined that there were no conditions or events that raise substantial doubt about the Company's ability to continue as a going concern and the Company will continue to meet its obligations through November 1, 2025.

(t) New Accounting Standards

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.* ASU 2016-13 requires financial assets measured at amortized cost to be presented at the net amount expected to be collected. The measurement of expected credit losses is based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amounts. An entity must use judgment in determining the relevant information and estimation methods that are appropriate in its circumstances. ASU 2016-13 is effective for annual reporting periods beginning after December 15, 2022, and a modified retrospective approach is required, with a cumulative effect adjustment to net assets as of the beginning of the first reporting period in which the guidance is effective. The Company adopted this ASU effective July 1, 2023 with no material impact.

(3) Investments and Investment Income

Investments at June 30 consisted of the following:

	 2024	2023
Short-term investments:		
Cash and cash equivalents	\$ 89,009	76,445
U.S. government notes		9,096
Fixed income bonds – corporate		1,016
Mutual funds		8,611
Mortgage backed securities		696
Asset backed securities		3,725
Alternative investments	 	28,181
Total	\$ 89,009	127,770

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

	 2024	2023
Assets whose use is limited:		
Cash and cash equivalents	\$ 64,010	13,408
Fixed income:		
Corporate debt securities	33,761	48,348
Mortgage backed securities	1,239	122
Asset backed securities	1,236	2,972
US government notes	5,366	4,483
Equities:		
Mutual funds	45,294	22,370
Institutional funds:		
Domestic equities	40,604	33,684
International equities	16,028	9,769
Fixed income	_	1,455
Alternative investments	 143,636	129,398
Total	\$ 351,174	266,009

The amount of the board designated funds whose use is limited is \$262,235 and \$232,520 as of June 30, 2024 and 2023, respectively.

Investment returns, net included in the consolidated statements of operations and changes in net assets comprise the following for the years ended June 30:

	 2024	2023
Investment returns, net:		
Interest and dividends, net of investment fees of \$424		
and \$578 in 2024 and 2023, respectively	\$ 9,178	5,757
Net realized gains on investments	4,360	731
Change in unrealized gains on investments	 27,634	20,448
	\$ 41,172	26,936

As of June 30, 2024 and 2023, the Hospital had invested \$16,287 and \$14,639, or 11.3% and 9.3%, respectively, of the portfolio in certain alternative investments, which are invested in hedge funds. The

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

following table summarizes redemption terms for the hedge fund-of-funds vehicles held as of June 30, 2024:

	Fund 1	Fund 2
Redemption timing:		
Redemption frequency	Quarterly	Quarterly
Required notice	65 days	100 days

At June 30, 2024 and 2023, the Company has invested in \$232,209 and \$226,101 of investments and assets whose use is limited for which the value is based on either readily determinable fair value (RDFV) or net asset value (NAV). At June 30, 2024, \$88,573 was based on RDFV and \$143,636 was based on NAV. At June 30, 2023, \$68,522 was based on RDFV and \$157,579 was based on NAV. At June 30, 2024 and 2023, \$127,349 and \$142,940, respectively, of assets based on NAV are commingled funds with the majority having redemption terms of five days or less.

The redemption terms and notification requirements of the institutional funds range from daily to monthly.

(4) Fair Value Measurements

Meritus measures fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The accounting guidance outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

- Level I Quoted prices are available in active markets for identical assets or liabilities as of the report date. A quoted price for an identical asset or liability in an active market provides the most reliable fair value measurement because it is directly observable to the market.
- Level II Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the report date. The nature of these securities include investments for which quoted prices are available but traded less frequently and investments that are fair valued using other securities, the parameters of which can be directly observed.
- Level III Securities that have little to no pricing observability as of the report date. These securities are measured using management's best estimate of fair value, where the inputs into the determination of fair value are not observable and require significant management judgment or estimation.

Financial instruments consist of cash equivalents, patient accounts receivable, investments, excluding those accounted for by the equity method, accounts payable and accrued expenses, and long-term debt. The carrying amounts reported in the consolidated balance sheets for cash equivalents, patient accounts receivable, and accounts payable and accrued expenses approximate fair value. Management's estimates of other financial instruments are described elsewhere in the notes to the consolidated financial statements.

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

Meritus does not have any Level 3 financial instruments as of June 30, 2024 or 2023.

Investments are valued using a market approach as follows:

Cash and cash equivalents – Cash equivalents are classified as Level 1 inputs and represent short-term, highly liquid investments that are readily convertible to cash and have original maturities of three months or less.

Stock and equity/institutional funds – Common stock and equity funds consist of stock and are valued based upon unadjusted quoted prices in the market.

Mutual Funds – Valued at the closing price reported in the active market in which the mutual fund is traded.

Fixed income bonds – Valued at the closing price reported in the active market in which the bond is traded.

The following table presents Meritus' assets measured at fair value on a recurring basis using the market approach, as of June 30:

	_	Level 1	Level 2	Level 3	_	Total
2024:						
Cash and cash equivalents	\$	153,019	_	_		153,019
Mutual funds		45,294	_	_		45,294
Fixed income bonds:						
Corporate debt securities		_	33,761	_		33,761
Mortgage-backed securities		_	1,239	_		1,239
Asset backed securities		_	1,236	_		1,236
U.S. government notes		_	5,366	_		5,366
Institutional funds:						
Domestic equities		_	40,604	_		40,604
International equities		_	16,028	_		16,028
Fixed income					_	
Total assets at fair value	\$	198,313	98,234		=	296,547
Assets at NAV					_	143,636
Total assets					\$	440,183

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

	 Level 1	Level 2	Level 3	_	Total
2023:					
Cash and cash equivalents	\$ 89,853	_	_		89,853
Mutual funds	30,981	_	_		30,981
Fixed income bonds:					
Corporate debt securities	_	49,364	_		49,364
Mortgage-backed securities	_	818	_		818
Asset backed securities	_	6,697	_		6,697
U.S. government notes	_	13,579	_		13,579
Institutional funds:					
Domestic equities	_	33,684	_		33,684
International equities	_	9,769	_		9,769
Fixed income	 	1,455		_	1,455
Total assets at fair value	\$ 120,834	115,366			236,200
Assets at NAV				_	157,579
Total assets				\$_	393,779

There were no Level 3 investments or transfers during the years ended June 30, 2024 or 2023.

(5) Property, Plant, and Equipment

Property, plant, and equipment at June 30 comprise the following:

	 2024	2023
Land	\$ 28,389	26,307
Buildings and improvements	261,916	249,043
Leasehold improvements	4,828	4,428
Equipment	 222,399	232,004
	517,532	511,782
Less accumulated depreciation and amortization	 (297,830)	(285,397)
	219,702	226,385
Construction in progress	 79,804	10,313
Property, plant, and equipment, net	\$ 299,506	236,698

Total depreciation and amortization expense for property, plant, and equipment for the years ended June 30, 2024 and 2023 was \$30,646 and \$29,733, respectively.

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

(6) Equity Investments in Affiliates

The following investments, recorded under the equity method of accounting, are included in the consolidated balance sheets.

The Hospital holds a 25% equity interest in Maryland Care, Inc. (MPC), a managed care organization (MCO) that was established to serve Maryland's Medicaid population as a result of the State's requirement for Medicaid patients to be a member of an MCO, and Maryland Care Management, Inc. (MCMI), a management services organization that provides management services to MPC. The Hospital holds a 41% equity interest in Cumberland Valley Surgery Center, LLC, an ambulatory surgery center.

Holdings holds a 50% interest in GSRE which is a real estate holding company. MEI has a 50% interest in DIS, which provides radiology imaging services.

Summary of financial information as of June 30, 2024 and 2023 and for the years then ended appears below for the significant equity investments:

					Diagnostic			
			Maryland Care, Inc.		Imaging Serv	rices, LLC		
		_	2024	2023	2024	2023		
Assets		\$	408,440	484,638	14,641	10,187		
Liabilities		_	264,498	258,307	7,363	3,826		
	Equity	\$_	143,942	226,331	7,278	6,361		
Revenue		\$	1,402,380	1,438,003	24,063	20,988		
Expenses		_	1,353,868	1,370,940	21,824	20,170		
	Net income	\$_	48,512	67,063	2,239	818		
		N	Maryland Care Ma	anagement, Inc.				
		_	2024	2023				
Assets		\$	18,722	18,350				
Liabilities		_	3,846	5,040				
	Equity	\$_	14,876	13,310				
Revenue		\$	29,083	28,033				
Expenses		_	27,517	27,034				
	Net income	\$_	1,566	999				

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

(7) Long-Term Debt

Long-term debt at June 30 consists of the following:

	 2024	2023
MHHEFA Revenue Bonds: Series 2015 3.50%–5.00% serial bonds, including issue		
premiums of \$10,570	\$ 229,687	235,928
Series 2022 2.59%	 57,926	60,350
	287,613	296,278
Less current portion of long-term debt	(8,759)	(8,491)
Less debt issuance costs and discounts	 (1,708)	(1,882)
	\$ 277,146	285,905

On July 9, 2015, Meritus issued Series 2015 Bonds to (i) refund all of the Maryland Health and Higher Educational Facilities Authority's Revenue Bonds, Washington County Hospital Issue, Series 2008 (Series 2008 Bonds) and (ii) finance and refinance the cost of construction, renovation, and equipping of certain additional facilities for Meritus (the 2015 Project). The Series 2015 Bonds were issued in the principal amount of \$257,300 plus a premium of \$15,100. The Series 2015 Bonds proceeds, together with the outstanding Series 2008 Bonds escrow fund balance totaled \$22,000, and Meritus' internal cash of \$7,400 were used to pay the cost of issuance, refund Series 2008 Bonds and receive \$20,000 of proceeds for capital expenditures. The Series 2015 Bonds are due in annual principal installments through 2045 and bear interest at 3.5% to 5.0% due semiannually in January and July.

The long-term debt related to the Series 2015 Bonds is reflected in the consolidated financial statements including the unamortized bond premium. The original issue bond premiums are being amortized over the life of the debt and are netted against interest expense in the consolidated statements of operations and changes in net assets.

On March 9, 2022, Meritus issued a taxable bond in the amount of \$60,350 (Series 2022 Bond) to finance past capital expenditures and pay for the cost of issuance. Maryland Health and Higher Educational Facilities Authority (MHHEFA) and Meritus amended the Master Loan Agreement dated as of July 1, 2015 to recognize the Series 2022 Bond as a parity debt by executing the First Supplemental Master Loan Agreement dated as of March 1, 2022. The Series 2022 Bond are due in various annual principal repayments commencing July 1, 2023 through 2037, and bears a fixed interest at 2.59% due monthly.

All bonds are collateralized by a first lien and claims on all receipts of Meritus, except restricted donations and contributions. In connection with the Series 2015 Bonds, the bond holders have a security interest in existing facilities of Meritus. All bonds require the Hospital to maintain certain financial ratios and stipulated insurance coverage as defined.

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

Scheduled principal repayments on long-term debt are as follows for the next five years as of June 30:

2025	\$ 8,759
2026	9,094
2027	9,539
2028	9,808
2029	10,185
Thereafter	 240,228
	\$ 287,613

(8) Leases Commitments

Meritus accounts for leases in accordance with Accounting Standards Codification (ASC) Topic 842, Leases, and determines if an arrangement contains a lease at the inception of the contract. Right-of-use assets and liabilities are recognized at the contract commencement date for the present value of lease payments over the lease term. Meritus uses its estimated incremental borrowing rate when no implicit rate is noted within the contract. A right-of-use asset and lease liability is not recognized for leases with an initial term of 12 months or less and rent expense for these types of leases are recognized on a straight-line basis over the lease term, or when incurred if a month-to-month lease.

Meritus utilizes operating leases primarily for real estate, including medical facilities and office space. The real estate lease agreements have initial terms of 5 to 20 years. Some real estate leases include one or more options to renew, the exercise of lease renewal options is at the Hospital's discretion. When determining the lease term, options to extend or terminate the lease were included when it was reasonably certain the Meritus would exercise that option.

Supplemental balance sheet information related to leases as of June 30 are as follows:

	Balance sheet classification	2024	2023	
Operating leases:				
Operating lease ROU assets - current	Prepaid and other current assets	\$	3,699	3,487
Operating lease ROU assets - noncurrent	Other assets		24,581	26,830
Operating lease ROU liabilities - current	Accounts payable and accrued expense	es.	3,699	3,487
Operating lease ROU liabilities - noncurrent	Other long-term liabilities		24,581	26,830

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

Supplemental cash flow and other information related to leases as of and for the years ended June 30 are as follows:

Other information	 2024	2023
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from operating leases (1)	\$ 2,036	1,979
Weighted average remaining lease term:		
Operating leases	10 Years	11 Years
Weighted average discount rate:		
Operating leases	4.4 %	4.4 %

(1) Included in other assets and accounts payable, accrued expenses, and long-term liabilities in the statement of cash flows

Future maturities of operating lease liabilities as of June 30, 2024 are as follows:

	Leases
Year ending June 30:	
2025	\$ 5,066
2026	4,494
2027	3,816
2028	3,736
2029	3,615
Thereafter	14,848
Total minimum lease payments	35,575
Impact of present value discount	(7,295)
Present value of minimum lease	
payments	\$ 28,280

The components of the lease cost and rent expense, which is recorded within supplies and other in the consolidated statements of operations and changes in net assets for the years ended June 30 are as follows:

Lease cost		2024	2023
Operating lease cost:			
Operating lease cost	\$	4,909	4,451
Short-term lease expense		1,024	1,184
Total operating lease cost	\$	5,933	5,635

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

(9) Income Taxes

Holdings and its subsidiaries file a consolidated federal return and separate state returns. The income tax (benefit) expense for the years ended June 30 consists of:

		2024	2023
Current:			
Federal	\$	(65)	(207)
State		(46)	(70)
	\$_	(111)	(277)
Deferred:			
Federal	\$	(301)	2
State			
	\$	(301)	2

The significant components of the deferred tax assets and deferred tax liabilities, which are included in prepaid and other current assets and other assets at June 30, are as follows:

	 2024	2023
Deferred tax asset:		
Accrued vacation	\$ 120	107
Deferred compensation	276	423
Allowance for bad debts	30	23
NOL carryover	910	1,103
Fixed assets	138	138
Other	 167	141
	 1,641	1,935
Deferred tax liabilities:		
Unrealized gain/loss	(36)	(29)
Captive insurance premiums	 (11)	(11)
	 (47)	(40)
	\$ 1,594	1,895

In assessing deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based upon

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

positive operation trends through 2024 and projections for future taxable income, management believes that it is more likely than not that the Company will realize the benefits of the deductible differences at June 30, 2024 and 2023. Accordingly, the Company has determined that there is no valuation allowance as of June 30, 2024 or 2023. The amount of the deferred tax asset considered realizable, however, could be reduced in the near term if estimates of future taxable income during the carryforward period are reduced.

As of June 30, 2024 or 2023, the Company has no unrecognized tax benefits. Therefore, the Company does not expect any impact on the effective tax rate related to recognition of unrecognized tax benefits. In addition, there are no anticipated reversals of uncertain tax positions in the next 12 months. The Company's policy is to recognize interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of June 30, 2024 or 2023, the Company has no accrued interest or penalties related to uncertain tax positions.

(10) Post Retirement Benefit Plans

Defined Contribution Plans

Meritus has a 401(k) Savings Plan. The plan is available to all Meritus employees. Meritus matches employee contributions for an amount up to 6% of each employee's base salary, subject to limitations.

Amounts charged to expense for the years ended June 30, 2024 and 2023 were \$8,799 and \$7,835, respectively.

The Hospital and MEI each maintain an employee funded supplemental nonqualified retirement plan for certain employees. The plan requires the benefits be paid upon termination, retirement, or death. The related liability is \$8,891 and \$6,451 at June 30, 2024 and 2023, respectively. Management has designated investments for the intended purpose of funding the liability when payable.

(11) Insurance Coverage

Meritus has a wholly owned insurance captive, MIC, to provide primary limits of insurance of \$1,000 per occurrence/\$3,000 aggregate for professional and general liability. In addition, MIC purchased reinsurance in the amount of \$30,000 to cover any potential liabilities above the \$1,000/\$3,000 primary limits, which were covered by MIC. The self-insured liabilities determined by an actuary for professional and general liability claims are included in other long-term liabilities in the consolidated balance sheets. As of June 30, 2024 and 2023, Meritus recorded a liability of \$17,188 and \$6,820, respectively.

Consistent with most companies with similar insurance operations, the liability for losses is ultimately based on management's reasonable expectations of future events. It is reasonably possible that the expectations associated with these amounts could change in the near term (i.e., within one year) and that the effect of such changes could be material to the consolidated financial statements.

In 2024 and 2023, the Company participated in a self-insured plan for workers' compensation claims. Stop-loss coverage has been purchased through a commercial carrier for claims in excess of \$450. As of June 30, 2024 and 2023, Meritus recorded a liability of \$2,250 and \$2,300, which is included in accrued salaries, wages, and withholdings in the consolidated balance sheets.

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

(12) Risk and Uncertainties

The Company provides general acute healthcare services in the State of Maryland. The Company and other healthcare providers are subject to certain inherent risks, including the following:

- Dependence on revenues derived from reimbursement by the federal Medicare and state Medicaid programs
- Regulation of hospital rates by the State of Maryland Health Services Cost Review Commission
- Government regulation, government budgetary constraints, and proposed legislative and regulatory changes
- · Lawsuits alleging malpractice or other claims.

Such inherent risks require the use of certain management estimates in the preparation of the Company's consolidated financial statements and it is reasonably possible that a change in such estimates may occur.

The Medicare and state Medicaid reimbursement programs represent a substantial portion of the Company's revenues and the Company's operations are subject to a variety of other federal, state, and local regulatory requirements. Failure to maintain required regulatory approvals and licenses and/or changes in such regulatory requirements could have a significant adverse effect on the Company.

Changes in federal and state reimbursement funding mechanisms and related government budgetary constraints could have a significant adverse effect on the Company.

The federal government and many states have aggressively increased enforcement under Medicare and Medicaid antifraud and abuse laws and physician self-referral laws (STARK law and regulation). Federal healthcare reform initiatives continue to prompt a national review of federally funded healthcare programs. In addition, the federal government and many states continue to fund programs to audit and recover potential overpayments to providers from the Medicare and Medicaid programs. The Company has devoted resources to implement a compliance program to monitor conformance with applicable laws and regulations, but the possibility of future government review and enforcement action exists. However, any negative findings from a future proceeding, if any, could result in substantial financial penalties or awards against the Company, exclusion from future participation in the Medicare and Medicaid programs, and if criminal proceedings were initiated against the Company, possible criminal penalties. At this time, the Company cannot predict the ultimate outcome of any potential inquiries, or the potential range of damages, if any.

As a result of recently enacted and pending federal healthcare reform legislation, substantial changes are anticipated in the United States healthcare system. Such legislation includes numerous provisions affecting the delivery of healthcare services, the financing of healthcare costs, reimbursement to healthcare providers, and the legal obligations of health insurers, providers, and employers. These provisions are currently slated to take effect at specified times over the next decade. This federal healthcare reform legislation did not affect the 2024 or 2023 consolidated financial statements.

The Company recognizes the increasing importance of cybersecurity in today's digital landscape. As a result, the Company has implemented various measures to mitigate the risk of cyber threats and protect

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

our systems and data as well as monitor the risks our vendors have. However, we understand that no system is completely immune to cyberattacks, and there is a possibility that an unauthorized access, data breach, or other cybersecurity incident may occur at either one of our systems or at one of vendors' systems. In the event of a significant cyber incident, there could be a significant impact to the Company's future operating results, financial condition, or liquidity. However, to mitigate the potential impact to the Company's future operating results, financial condition, or liquidity. However, to mitigate the potential impact to the Company if such an event were to occur, the Company maintains cyber insurance coverage. While we believe our cybersecurity measures and our vendors' measures are robust, there can be no assurance that they will prevent all cyber threats or that there will be a cyber incident in the future that may not have a significant adverse effect on our financial condition, liquidity, or results of operations.

Litigation

Additionally, Meritus is involved in litigation and regulatory investigations arising in the course of business. After consultation with legal counsel, management estimates that these matters will be resolved without a material adverse effect on Meritus' financial position or results of operations.

(13) Functional Expenses

Meritus provides general healthcare services to residents within its geographic location. Expenses related to providing these services for the years ended June 30 are as follows:

	_	Program services	General and administrative	Fundraising	Total
2024:					
Salaries and wages	\$	239,203	43,317	_	282,520
Employee benefits		43,038	8,706	_	51,744
Professional fees		38,570	6,886	_	45,456
Supplies and other		141,904	34,012	312	176,228
Interest		8,932	2,756	_	11,688
Depreciation and amortization		24,614	6,032		30,646
Total expenses	\$_	496,261	101,709	312	598,282

Notes to Consolidated Financial Statements

June 30, 2024 and 2023

(Dollars in thousands)

	_	Program services	General and administrative	Fundraising	Total
2023:					
Salaries and wages	\$	200,467	41,060	_	241,527
Employee benefits		38,264	7,837	_	46,101
Professional fees		34,453	7,057	_	41,510
Supplies and other		124,592	25,349	260	150,201
Interest		9,847	2,017	_	11,864
Depreciation and amortization	_	24,678	5,055		29,733
Total expenses	\$	432,301	88,375	260	520,936

(14) Liquidity and Availability of Financial Assets

The following reflects financial assets as of June 30, 2024 and 2023, reduced by amounts not available for general expenditure because of contractual or donor-imposed restrictions within one year.

	 2024	2023
Financial assets as of June 30	\$ 533,856	490,711
Less those unavailable for general expenditures		
within one year, due to:		
Contractual and donor-imposed restriction:		
Funds designated for insurance purpose	(16,276)	(14,837)
Assets held by trustee	(62,614)	(11,049)
Supplemental retirement benefits investment	(8,891)	(6,451)
Donor restricted	 (1,157)	(1,151)
Financial assets available within one year to meet cash needs for general expenditures within		
one year	\$ 444,918	457,223

Included in financial assets available are \$262,235 and \$232,520 of funds set aside for long-term investments as designated by the Board of Directors as of June 30, 2024 and 2023, respectively.

(15) Subsequent Events

Meritus evaluated subsequent events through October 31, 2024, the date these consolidated financial statements were issued. Effective July 1, 2024, Meritus has affiliated with Brook Lane to expand access to mental health services across the region and state. Brook Lane will be included in the Meritus consolidated financial statements beginning July 1, 2024. All other material matters are disclosed in the notes to the consolidated financial statements.



Consolidating Balance Sheet

June 30, 2024

(Dollars in thousands)

Assets		Meritus Medical Center	Meritus Health Foundation	MSOM	Meritus other	Consolidating total	Consolidating entries	Consolidated total
Current assets:								
Cash and cash equivalents	\$	9,723	18	_	2,899	12,640	_	12,640
Short-term investments		89,009	_	_	_	89,009	_	89,009
Current portion of assets whose use is limited		62,614	_	_	_	62,614	_	62,614
Accounts receivable		51,852	_	_	10,080	61,932	_	61,932
Supplies		10,934	_	_	1,091	12,025	_	12,025
Prepaid and other current assets	_	30,172	2,407	(4,077)	4,902	33,404	(7,880)	25,524
Total current assets		254,304	2,425	(4,077)	18,972	271,624	(7,880)	263,744
Assets whose use is limited		265,240	6,042	_	17,278	288,560	_	288,560
Property, plant, and equipment, net		289,716	_	1,146	8,644	299,506	_	299,506
Equity investments in affiliates		43,359	_	_	3,748	47,107	(3,124)	43,983
Other assets	_	28,947	4,085		23,598	56,630	(10,106)	46,524
Total assets	\$_	881,566	12,552	(2,931)	72,240	963,427	(21,110)	942,317

Consolidating Balance Sheet

June 30, 2024

(Dollars in thousands)

Liabilities and Net Assets	Meritus Medical Center	Meritus Health Foundation	MSOM	Meritus other	Consolidating total	Consolidating entries	Consolidated total
Current liabilities:							
Accounts payable and accrued expenses	\$ 42,747	_	1,249	8,395	52,391	_	52,391
Accrued salaries, wages, and withholdings	12,745	_	258	1,386	14,389	_	14,389
Accrued compensation benefit	11,228	_	256	2,936	14,420	_	14,420
Advances from third-party payors	14,658	_	_	2,398	17,056	_	17,056
Accrued interest payable	5,314	_	_	_	5,314	_	5,314
Current portion of long-term debt	8,759				8,759		8,759
Total current liabilities	95,451	_	1,763	15,115	112,329	_	112,329
Long-term debt, net of current portion	277,146	_	_		277,146	_	277,146
Accrued retirement benefits	7,889	_	_	1,002	8,891	_	8,891
Other long-term liabilities	15,142			34,454	49,596	(7,880)	41,716
Total liabilities	395,628		1,763	50,571	447,962	(7,880)	440,082
Stockholder's equity:							
Common stock	_	_	_	820	820	(820)	_
Paid-in capital				1,150	1,150	(1,150)	
Total stockholders' equity				1,970	1,970	(1,970)	
Net assets:							
Net assets without donor restrictions	474,458	2,442	(4,694)	19,699	491,905	(1,154)	490,751
Net assets with donor restrictions	11,480	10,110		<u> </u>	21,590	(10,106)	11,484
Total net assets	485,938	12,552	(4,694)	19,699	513,495	(11,260)	502,235
Total liabilities and net assets	\$ 881,566	12,552	(2,931)	72,240	963,427	(21,110)	942,317

See accompanying independent auditors' report.

Consolidating Statement of Operations and Changes in Net Assets

Year ended June 30, 2024

(Dollars in thousands)

Fiscal period ending June 30, 2024		Meritus Medical Center	Meritus Health Foundation	MSOM	Meritus other	Consolidating total	Consolidating entries	Consolidated total
Unrestricted revenue, gains and other support:								
Net patient revenue	\$	458,783	_	_	136,359	595,142	(15,536)	579,606
Other revenue		27,218	_	3	5,907	33,128	(5,519)	27,609
Equity earnings in affiliates		13,044	_	_	1,145	14,189	_	14,189
Net assets released from restriction used for operations	_	181	205			386	(204)	182
	_	499,226	205	3	143,411	642,845	(21,259)	621,586
Operating expenses:								
Salaries and wages		203,123	_	1,858	77,539	282,520	_	282,520
Employee benefits		38,586	_	507	13,171	52,264	(520)	51,744
Professional fees		21,348	_	_	24,108	45,456	_	45,456
Supplies and other		133,894	130	2,332	60,407	196,763	(20,535)	176,228
Interest		11,685	_	_	3	11,688	_	11,688
Depreciation and amortization	_	26,899	(2)		3,749	30,646		30,646
	_	435,535	128	4,697	178,977	619,337	(21,055)	598,282
Operating income (loss)		63,691	77	(4,694)	(35,566)	23,508	(204)	23,304
Nonoperating gains (losses), net:								
Investment returns, net		39,265	594	_	1,313	41,172	_	41,172
Other, net	_	(64)	(1,296)		(373)	(1,733)	204	(1,529)
Excess (deficit) of revenue over expenses	\$_	102,892	(625)	(4,694)	(34,626)	62,947		62,947

Consolidating Statement of Operations and Changes in Net Assets

Year ended June 30, 2024

(Dollars in thousands)

Fiscal period ending June 30, 2024		Meritus Medical Center	Meritus Health Foundation	мѕом	Meritus other	Consolidating total	Consolidating entries	Consolidated total
Net assets without donor restrictions:								
Excess (deficit) of revenues over expenses	\$	102,892	(625)	(4,694)	(34,626)	62,947	_	62,947
Equity transfers		(44,528)	_	_	44,528	_	_	_
Other, net	_	978	872		2	1,852		1,852
Increase (decrease) in net assets without donor								
restrictions	_	59,342	247	(4,694)	9,904	64,799		64,799
Net assets with donor restrictions:								
Contributions		1,333	1,898	_	_	3,231	(1,131)	2,100
Other, net		(2,608)	(86)	_	_	(2,694)	2,585	(109)
Net assets released from restriction for capital		(950)	(950)	_	_	(1,900)	950	(950)
Net assets released from restriction for operations	_	(182)	(205)			(387)	205	(182)
(Decrease) increase in net assets with donor restrictions	_	(2,407)	657			(1,750)	2,609	859
Increase (decrease) in net assets		56,935	904	(4,694)	9,904	63,049	2,609	65,658
Net assets:								
Beginning of year	_	429,003	11,648		9,795	450,446	(13,869)	436,577
End of year	\$_	485,938	12,552	(4,694)	19,699	513,495	(11,260)	502,235

See accompanying independent auditors' report.